Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base

Int J Cardiol

25 Ottobre Ott 2022 one month ago
  • Salvioni E, Mapelli M, Bonomi A, Vignati C, Agostoni P.

The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation.

Reference: Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base. Toto F, Salvioni E, Magrì D, Sciomer S, Piepoli M, Badagliacca R, Galotta A, Baracchini N, Paolillo S, Corrà U, Raimondo R, Lagioia R, Filardi PP, Iorio A, Senni M, Correale M, Cicoira M, Perna E, Metra M, Guazzi M, Limongelli G, Sinagra G, Parati G, Cattadori G, Bandera F, Bussotti M, Mapelli M, Cipriani M, Bonomi A, Cunha G, Re F, Vignati C, Garascia A, Lombardi C, Scardovi AB, Passantino A, Emdin M, Passino C, Santolamazza C, Girola D, Zaffalon D, Vizza D, De Martino F, Agostoni P; MECKI score research group (see appendix). Int J Cardiol. 2022 Sep 14:S0167-5273(22)01340-7.

Go to PubMed